

# Jackson T Wright

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8405706/publications.pdf>

Version: 2024-02-01

67  
papers

15,531  
citations

147801

31  
h-index

118850

62  
g-index

68  
all docs

68  
docs citations

68  
times ranked

16603  
citing authors

#	ARTICLE	IF	CITATIONS
1	Self-Reported Antihypertensive Medication Class and Temporal Relationship to Treatment Guidelines. <i>Hypertension</i> , 2022, 79, 338-348.	2.7	6
2	Association of Intensive vs Standard Blood Pressure Control With Cerebral Blood Flow. <i>JAMA Neurology</i> , 2022, 79, 380.	9.0	26
3	MO094: Intensive Blood Pressure Lowering and Myocardial Fibrosis Biomarkers in Individuals With and Without CKD: Results From the Systolic Blood Pressure Intervention Trial (Sprint). <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.7	0
4	Effects of Intensive Blood Pressure Treatment on Orthostatic Hypotension. <i>Annals of Internal Medicine</i> , 2021, 174, 58-68.	3.9	47
5	The Targeted Management (TEAM) Intervention for Reducing Stroke Risk in African American Men: Rationale and Study Design of a Prospective Randomized Controlled Trial. <i>Journal of Multidisciplinary Healthcare</i> , 2021, Volume 14, 513-522.	2.7	1
6	Chronic kidney disease, atherosclerotic plaque characteristics on carotid magnetic resonance imaging, and cardiovascular outcomes. <i>BMC Nephrology</i> , 2021, 22, 69.	1.8	6
7	The Benefits of Intensive Versus Standard Blood Pressure Treatment According to Fine Particulate Matter Air Pollution Exposure. <i>Hypertension</i> , 2021, 77, 813-822.	2.7	13
8	Guideline-Driven Management of Hypertension. <i>Circulation Research</i> , 2021, 128, 827-846.	4.5	52
9	Policies to solve the salt problem. <i>Preventive Medicine</i> , 2021, 145, 106448.	3.4	1
10	Final Report of a Trial of Intensive versus Standard Blood-Pressure Control. <i>New England Journal of Medicine</i> , 2021, 384, 1921-1930.	27.0	214
11	Sex Differences in Cardiovascular Outcomes in CKD: Findings From the CRIC Study. <i>American Journal of Kidney Diseases</i> , 2021, 78, 200-209.e1.	1.9	23
12	SPRINT Revisited: Updated Results and Implications. <i>Hypertension</i> , 2021, 78, 1701-1710.	2.7	9
13	Serum bicarbonate and cardiovascular events in hypertensive adults: results from the Systolic Blood Pressure Intervention Trial. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1377-1384.	0.7	16
14	Intensive vs Standard Blood Pressure Control in Adults 80 Years or Older: A Secondary Analysis of the Systolic Blood Pressure Intervention Trial. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 496-504.	2.6	59
15	Orthostatic Hypotension, Cardiovascular Outcomes, and Adverse Events. <i>Hypertension</i> , 2020, 75, 660-667.	2.7	57
16	Association of Race/Ethnicity-Specific Changes in Antihypertensive Medication Classes Initiated Among Medicare Beneficiaries With the Eighth Joint National Committee Panel Member Report. <i>JAMA Network Open</i> , 2020, 3, e2025127.	5.9	9
17	Association of Intensive vs Standard Blood Pressure Control With Cerebral White Matter Lesions. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 524.	7.4	285
18	Blood Pressure Assessment in Adults in Clinical Practice and Clinic-Based Research. <i>Journal of the American College of Cardiology</i> , 2019, 73, 317-335.	2.8	114

#	ARTICLE	IF	CITATIONS
19	Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia. JAMA - Journal of the American Medical Association, 2019, 321, 553.	7.4	786
20	Rationale for Ambulatory and Home Blood Pressure Monitoring Thresholds in the 2017 American College of Cardiology/American Heart Association Guideline. Hypertension, 2019, 73, 33-38.	2.7	38
21	Sex-Related Disparities in CKD Progression. Journal of the American Society of Nephrology: JASN, 2019, 30, 137-146.	6.1	157
22	The Effects of eGFR Change on CVD, Renal, and Mortality Outcomes in a Hypertensive Cohort Treated With 3 Different Antihypertensive Medications. American Journal of Hypertension, 2018, 31, 609-614.	2.0	9
23	Potential U.S. Population Impact of the 2017 ACC/AHA High Blood Pressure Guideline. Journal of the American College of Cardiology, 2018, 71, 109-118.	2.8	283
24	Blood Pressure Measurement in SPRINT (Systolic Blood Pressure Intervention Trial). Hypertension, 2018, 71, 848-857.	2.7	190
25	Influence of metabolic syndrome and race on the relationship between intensive blood pressure control and cardiovascular outcomes in the SPRINT cohort. Diabetes, Obesity and Metabolism, 2018, 20, 629-637.	4.4	5
26	2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension, 2018, 71, e13-e115.	2.7	3,332
27	Risk Factors Influencing Outcomes of Atrial Fibrillation in ALLHAT. Journal of the National Medical Association, 2018, 110, 343-351.	0.8	2
28	Sprinting Toward the Optimal Blood Pressure Target for Hypertensive Patients. Circulation Research, 2018, 123, 531-534.	4.5	4
29	Poor Oral Health and Blood Pressure Control Among US Hypertensive Adults. Hypertension, 2018, 72, 1365-1373.	2.7	75
30	First-Year Anniversary of the 2017 Hypertension Guideline. Circulation, 2018, 138, 1774-1776.	1.6	1
31	Rapid eGFR change as a determinant of cardiovascular and renal disease outcomes and of mortality in hypertensive adults with and without type 2 diabetes. Journal of Diabetes and Its Complications, 2018, 32, 830-832.	2.3	6
32	Clinical Outcomes by Race and Ethnicity in the Systolic Blood Pressure Intervention Trial (SPRINT): A Randomized Clinical Trial. American Journal of Hypertension, 2018, 31, 97-107.	2.0	25
33	Effects of Intensive BP Control in CKD. Journal of the American Society of Nephrology: JASN, 2017, 28, 2812-2823.	6.1	364
34	Influence of Prevalent and Incident Atrial Fibrillation on Post-Trial Major Events in ALLHAT. Journal of the National Medical Association, 2017, 109, 172-181.	0.8	3
35	Coronary Artery Calcification and Risk of Cardiovascular Disease and Death Among Patients With Chronic Kidney Disease. JAMA Cardiology, 2017, 2, 635.	6.1	251
36	Baseline Quality of Life and Risk of Stroke in the ALLHAT Study (Antihypertensive and Lipid-Lowering) Treatment Comparison	2.0	3

#	ARTICLE	IF	CITATIONS
37	Associations of Conventional Echocardiographic Measures with Incident Heart Failure and Mortality: The Chronic Renal Insufficiency Cohort. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 60-68.	4.5	38
38	BP Control and Long-Term Risk of ESRD and Mortality. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 671-677.	6.1	71
39	Abstract 047: Clinical Outcomes by Race and Ethnicity in the Systolic Blood Pressure Intervention Trials (SPRINT): A Randomized Control Trial. <i>Hypertension</i> , 2017, 70, .	2.7	0
40	Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 2673.	7.4	991
41	Different components of blood pressure are associated with increased risk of atherosclerotic cardiovascular disease versus heart failure in advanced chronic kidney disease. <i>Kidney International</i> , 2016, 90, 1348-1356.	5.2	22
42	Orthostatic changes in systolic blood pressure among SPRINT participants at baseline. <i>Journal of the American Society of Hypertension</i> , 2016, 10, 847-856.	2.3	56
43	Reducing Health Inequities in the U.S.. <i>Journal of the American College of Cardiology</i> , 2016, 68, 517-524.	2.8	36
44	Sex Differences in the Incidence of Peripheral Artery Disease in the Chronic Renal Insufficiency Cohort. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, S86-93.	2.2	30
45	The Associations between Peripheral Artery Disease and Physical Outcome Measures in Men and Women with Chronic Kidney Disease. <i>Annals of Vascular Surgery</i> , 2016, 35, 111-120.	0.9	2
46	SPRINT Trial Results. <i>Hypertension</i> , 2016, 67, 263-265.	2.7	79
47	Real-World Evidence Supports Optimally Dosed Thiazide-Type Diuretics As Preferred in Treatment Regimens of Older Adults with Hypertension. <i>Journal of the American Geriatrics Society</i> , 2015, 63, 1045-1047.	2.6	2
48	Recognition and Management of Hypertension in Older Persons: Focus on African Americans. <i>Journal of the American Geriatrics Society</i> , 2015, 63, 2130-2138.	2.6	13
49	The effects of weight change on glomerular filtration rate. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1870-1877.	0.7	18
50	Baseline characteristics of African Americans in the Systolic Blood Pressure Intervention Trial. <i>Journal of the American Society of Hypertension</i> , 2015, 9, 670-679.	2.3	14
51	Apolipoprotein L1 gene variants associate with prevalent kidney but not prevalent cardiovascular disease in the Systolic Blood Pressure Intervention Trial. <i>Kidney International</i> , 2015, 87, 169-175.	5.2	71
52	A Randomized Trial of Intensive versus Standard Blood-Pressure Control. <i>New England Journal of Medicine</i> , 2015, 373, 2103-2116.	27.0	4,880
53	Blood Pressure and Risk of All-Cause Mortality in Advanced Chronic Kidney Disease and Hemodialysis. <i>Hypertension</i> , 2015, 65, 93-100.	2.7	122
54	Estimating Time to ESRD Using Kidney Failure Risk Equations: Results From the African American Study of Kidney Disease and Hypertension (AASK). <i>American Journal of Kidney Diseases</i> , 2015, 65, 394-402.	1.9	45

#	ARTICLE	IF	CITATIONS
55	Abstract W P172: Baseline Quality of Life and Risk of Stroke in the Antihypertensive and Lipid Lowering to Prevent Heart Attack (ALLHAT) Trial. <i>Stroke</i> , 2015, 46, .	2.0	1
56	The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: The Systolic Blood Pressure Intervention Trial (SPRINT). <i>Clinical Trials</i> , 2014, 11, 532-546.	1.6	408
57	Module 3: Using thiazide-type diuretics in African Americans with hypertension. <i>Journal of Family Practice</i> , 2012, 61, S20-2; quiz S31.	0.2	0
58	A 59-Year-Old Man With "Racial Characteristics". <i>Journal of Clinical Hypertension</i> , 2007, 9, 128-133.	2.0	10
59	Lowering Blood Pressure With $\beta$ -Blockers in Combination With Other Renin-Angiotensin System Blockers in Patients With Hypertension and Type 2 Diabetes: Results From the GEMINI Trial. <i>Journal of Clinical Hypertension</i> , 2007, 9, 842-849.	2.0	18
60	Antihypertensive efficacy of night-time graded-release diltiazem versus morning amlodipine in African Americans. <i>American Journal of Hypertension</i> , 2004, 17, 734-742.	2.0	12
61	Angiotensin-Converting Enzyme Inhibitors and Diuretics: Optimal Combination Therapy. <i>Annals of Internal Medicine</i> , 2004, 141, 893.	3.9	0
62	Determinants of Salt Sensitivity in Black and White Normotensive and Hypertensive Women. <i>Hypertension</i> , 2003, 42, 1087-1092.	2.7	97
63	Successful Blood Pressure Control in the African American Study of Kidney Disease and Hypertension. <i>Archives of Internal Medicine</i> , 2002, 162, 1636.	3.8	122
64	Effect of Blood Pressure Lowering and Antihypertensive Drug Class on Progression of Hypertensive Kidney Disease<SUBTITLE>Results From the AASK Trial</SUBTITLE>. <i>JAMA - Journal of the American Medical Association</i> , 2002, 288, 2421.	7.4	1,792
65	Blood Pressure Control in Hispanic Participants in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).. <i>Circulation</i> , 2001, 103, 1348-1348.	1.6	0
66	The Role of the Cytochrome P450-Dependent Metabolites of Arachidonic Acid in Blood Pressure Regulation and Renal Function A Review. <i>American Journal of Hypertension</i> , 1997, 10, 356-365.	2.0	76
67	Perindopril as monotherapy in hypertension: A multicenter comparison of two dosing regimens. <i>Clinical Pharmacology and Therapeutics</i> , 1993, 53, 479-484.	4.7	23